Adlai Nortye Group Ltd.
ANLHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeAdlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company carries a $998.8M market cap, placing it firmly in the small-cap category. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Market Cap
$998.8M
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-54.42
EPS (TTM)
$-0.66
EPS (Fwd)
$-0.28
ROE
-20.2%
ROA
-8.7%
Cash
$232.8M
Total Debt
$26.7M
Free CF
-$11.4M
52W Change
748.0%
Annual Financials
Cash vs Debt
Where ANL stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ANL finished 21.59% above its 150-day moving average ($11.21) and 54.89% above its 200-day moving average ($8.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANL overbought or oversold?
At the September 2, 2026 close, ANL's RSI(14) was 54.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $232.8M in cash comfortably exceeding the $26.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$11.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -20.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, ANL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ANL.